At Achillion, we are driven to transform the lives of patients and families affected by diseases of the complement system, an integral part of the innate immune system. Scientific and clinical evidence has implicated the complement system, and specifically the complement Alternative Pathway (AP), in numerous devastating diseases and conditions. Our principal focus at Achillion is to advance our clinical-stage portfolio of orally administered factor D inhibitors into late-stage development and potential commercialization for patients with devastating disorders of the complement system.
Sector:
Health Technology
Industry:
Biotechnology
Employees:
Frequently Asked Questions
What is Market Cap of Achillion Pharmaceuticals?
Market cap, also known as market capitalization, is the total market value of a company. It’s calculated by multiplying the current market price by the total number of shares outstanding. Achillion Pharmaceuticals market cap is N/A.
What is the 52-week high for Achillion Pharmaceuticals?
52 week high is the highest price of a stock in the past 52 weeks, or one year. Achillion Pharmaceuticals 52 week high is N/A as of September 28, 2025.
What is the 52-week low for Achillion Pharmaceuticals?
52 week low is the lowest price of a stock in the past 52 weeks, or one year. Achillion Pharmaceuticals 52 week low is N/A as of September 28, 2025.
What was Achillion Pharmaceuticals stock price yesterday?
Achillion Pharmaceuticals stock price yesterday was $6.76.
What is the PE ratio of Achillion Pharmaceuticals?
The Price-to-Earnings (or P/E) ratio is a commonly used tool for valuing a company. It’s calculated by dividing the current share price by the earnings per share (or EPS). It can also be calculated by dividing the company’s Market Cap by the Net Profit. Achillion Pharmaceuticals’s P/E ratio is None.
What is the Price-to-Book ratio of Achillion Pharmaceuticals?
The Price-to-Book (P/B) ratio is a commonly used tool for valuing a company. It’s calculated by dividing a company’s market capitalization by its book value. Achillion Pharmaceuticals P/B ratio is None.
What is Achillion Pharmaceuticals's EBITDA?
EBITDA is a widely used measure of corporate profitability. It stands for Earnings before Interest, Taxes, Depreciation, and Amortization. It attempts to reflect the cash profit generated by a company’s operations. Achillion Pharmaceuticals's EBITDA is -4.44.
What is the 50-day moving average of Achillion Pharmaceuticals?
The 50-day moving average is a frequently used data point by active investors and traders to understand the trend of a stock. It’s calculated by averaging the closing stock price over the previous 50 trading days. Achillion Pharmaceuticals 50-day moving average is N/A.
How many employess does Achillion Pharmaceuticals has?
